Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.

JCI insight - 10 Oct 2022

Taskinen Marja-Riitta, Björnson Elias, Matikainen Niina, Söderlund Sanni, Rämö Joel, Ainola Mari-Mia, Hakkarainen Antti, Sihlbom Carina, Thorsell Annika, Andersson Linda, Bergh Per-Olof, Henricsson Marcus, Romeo Stefano, Adiels Martin, Ripatti Samuli, Laakso Markku, Packard Chris J, Borén Jan

Abstract excerpt

BackgroundApolipoprotein C-III (apoC-III) is a regulator of triglyceride (TG) metabolism, and due to its association with risk of cardiovascular disease, is an emergent target for pharmacological intervention. The impact of substantially lowering apoC-III on lipoprotein metabolism is not clear.MethodsWe investigated the kinetics of apolipoproteins B48 and B100 (apoB48 and apoB100) in chylomicrons, VLDL1, VLDL2,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein C-III
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carrier Proteins

Share to Chylomicrons

Share to Lipoproteins

Share to Lipoproteins, VLDL

Share to Mutation

Share to Triglycerides

Source

Open in PubMed Open full text

Identifiers

PMID: 36040803
DOI: 10.1172/jci.insight.160607
PMCID: PMC9675484

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations.PMID 36040803Read ↗

Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.Semantic proximity Read ↗

Beneficial metabolic phenotypes caused by loss-of-function APOC3 mutations.Semantic proximity Read ↗

Metabolic Characterization of a Rare Genetic Variation Within APOC3 and Its Lipoprotein Lipase-Independent Effects.Semantic proximity Read ↗

Metabolomic signature of angiopoietin-like protein 3 deficiency in fasting and postprandial stateSemantic proximity Read ↗

Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.Semantic proximity Read ↗

[Mutations of APOC3 gene, metabolism of triglycerides and reduction of ischemic cardiovascular events].Semantic proximity Read ↗

Metabolic characterisation of disturbances in the APOC3/triglyceride-rich lipoprotein pathway through sample-based recall by genotype.Semantic proximity Read ↗

The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response.Semantic proximity Read ↗

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.Semantic proximity Read ↗

APOC3 Loss-of-Function Mutations, Remnant Cholesterol, Low-Density Lipoprotein Cholesterol, and Cardiovascular Risk: Mediation- and Meta-Analyses of 137 895 Individuals.Semantic proximity Read ↗

Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia.Semantic proximity Read ↗

Two novel mutations in apolipoprotein C3 underlie atheroprotective lipid profiles in families.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.